User Controls
Posts by MexicanMasterRace
-
2020-05-21 at 4:01 AM UTC in OKAY WHAT THE FUCK- Apparently some people don't have an internal monologue??!?!?!?
Originally posted by aldra I uh
I don't hear voices in my head. thoughts are just ideas, outside of that it's hard to explain how to access them, I just do
typically when I write I I don't 'hear' things before, only after when I look over it to make sure I haven't fucked up
That is fucking baffling.
I 'hear' everything I think. It's in words. Before I write, as I'm writing, and after I write. I'll think the entire sentence through, as well as variations of it. It's like spelling it out in my head. The thoughts are obviously not audible like hallucinations but very clear and just as 'loud' as speaking.
Do you relate to the visual stuff mentioned at all? -
2020-05-21 at 3:58 AM UTC in OKAY WHAT THE FUCK- Apparently some people don't have an internal monologue??!?!?!?What's interesting is that they both have insomnia but for different reasons.
"I can't stop the images"
"I can't stop the thoughts"
This is
fuck
what
it explains so much but
what -
2020-05-21 at 3:56 AM UTC in OKAY WHAT THE FUCK- Apparently some people don't have an internal monologue??!?!?!?"If I have a thought normally I say it out loud"
WH
WHAT -
2020-05-21 at 3:56 AM UTC in OKAY WHAT THE FUCK- Apparently some people don't have an internal monologue??!?!?!?You know that voice in your head? Yeah. The voice in your head. The one that speaks your thoughts.
Apparently not everyone has it. I guess it's not that they don't think so much as they don't hear their own thoughts. It seems to be more... visual? What the fuck. I have never heard of this or considered it. I thought everybody had an internal voice. Do you guys have a voice in your head?
-
2020-05-21 at 3:48 AM UTC in do people living at high altitudes feel like supeheroz when they come down to our petty level
-
2020-05-21 at 3:35 AM UTC in arab mindset is to be a dipshit / shitheadInshallah homie
-
2020-05-21 at 3:29 AM UTC in Best Remixes/editions of songs THE THREAD: The Movie, now playing in select theaters.
-
2020-05-21 at 3:27 AM UTC in I tried to talk a kid out of doing heroin the other night
Originally posted by gadzooks So I'm drinking in the parking lot (it's where all the cool kids in town go to get their drink on).
This one guy pulls out a piece of tin foil.
SIDENOTE: I used to be a heroin addict, so obviously I immediately associate foil with heroin use. Especially if you're pulling that shit out in a fucking parking lot. I know you're not about to unwrap a grilled cheese sandwich.
Well, I start telling the less opiate-experienced one that he's in for a wild fucking ride if he hits that shit.
The other kid starts dropping rationalizations (and I recognize every single one of them from having dropped them all myself back in my time).
Then the one more experienced kid, of course, asks me what I even know about all this shit.
Then I ask him why he isn't shooting it.
I straight up called them both pussies for smoking their shit when they could be getting 100% return on their investment by mainlining it.
I could tell that the one kid was more receptive to my shit. The other one, he's gone/done. He will be using the needle in a year or two. That's an established fact.
Now I'm worried about the other kid though. Actually, both of them. They were like 20 years old and throwing their lives away.
I've met kids like that and it honestly hurts so much. You see that they're going to fuck up their shit.
My friend's brother is like that but he's finally getting it together and is in rehab. -
2020-05-21 at 3:09 AM UTC in "Mass Shooting" in Nova Scotia, Canadastill you
-
2020-05-21 at 3:09 AM UTC in do people living at high altitudes feel like supeheroz when they come down to our petty levelThe increased oxygen must make them feel some kinda way. I bet it feels pretty awesome for them. Imagine spending your whole life in a low oxygen environment, your ancestors living there so long you've become genetically adapted to it... then you climb down from the mountain and realize that the air below your home gets you high.
shit is dank fire ass fpfudkfcking -
2020-05-21 at 3:03 AM UTC in I like black womenNot attracted to black women in the slightest.
-
2020-05-21 at 3:01 AM UTC in What happened to hydroxychloriquine?
-
2020-05-21 at 2:59 AM UTC in The Retarded Thread: Get off that bus edition
-
2020-05-21 at 2:09 AM UTC in "Mass Shooting" in Nova Scotia, CanadaSudo is fucking dumb and gets dicked around easily.
-
2020-05-21 at 2:09 AM UTC in What happened to hydroxychloriquine?
-
2020-05-21 at 1:02 AM UTC in The Retarded Thread: Get off that bus editioni dont want to be awake anymore make it stop
-
2020-05-21 at 12:38 AM UTC in what's the last thing you bought?
Originally posted by Daddyissues Lol. Tf.
He legit wears these like some kind of alley rat italian porn producer
It's so fucking gaudy and low class. Poor people usually buy flashy jedielry like this because its a tangible and visible liquid asset. "Look at me, I'm not poor! I have GOLD!" Rich people do the same thing but with stuff that's actually expensive, like nice cars or homes that are way too big for their family. -
2020-05-21 at 12:31 AM UTC in The longest thread on the internet! Free custom LOLcats inside! Ask within!
Originally posted by OMGPLZUNBAN Alright. I need phone calls of people leaving voicemails breaking up with me for a funny video idea. You need to end it with, "And where's my fucking cat?!"
I'm willing to give out my number for this idea.
MexicanMasterRace, you got me right?
No, you're a fucking racist you white piece of shit. I'd kill you and your entire race if I had the chance. -
2020-05-21 at 12:31 AM UTC in What happened to hydroxychloriquine?Home
News & Perspective
Infectious Disease Topics
Antimicrobial Stewardship
Ongoing Programs
About Us
DONATE NOW
FEATURED NEWS TOPICSNovel CoronavirusEbolaMERS-CoVChronic Wasting Disease
Study calls into question use of malaria drug for COVI D-19
Filed Under: COVID-19
Chris Dall | News Reporter | CIDRAP News | Apr 23, 2020
Share Tweet LinkedIn Email Print & PDF
hydroxychloroquine_tablets.jpg
Hydroxychloroquine tablets
Bartek Szewczyk / iStock
A retrospective study of patients with COVID-19 at Veterans Affairs (VA) hospitals found no evidence that the antimalaria drug hydroxychloroquine, either with or without the antibiotic azithromycin, reduced mortality or the need for mechanical ventilation.
Researchers also found that hydroxychloroquine alone was associated with increased mortality.
The findings, published this week on the preprint server medRxiv, suggest hydroxychloroquine may not have as much promise for treating COVID-19 patients as initially hoped. The study was not a randomized controlled trial, so the implications of the findings are limited, and the results have not been peer-reviewed. Still, the authors say the results suggest clinicians need to be careful about using the drug in COVID-19 patients.
"Data from ongoing, randomized controlled studies will prove informative when they emerge," they wrote. "Until then, the findings from this retrospective study suggest caution in using hydroxychloroquine in hospitalized COVID-19 patients, particularly when not combined with azithromycin."
No benefit found
For the study, researchers with Columbia VA Health Care System, the University of South Carolina, and the University of Virginia School of Medicine looked at data from 368 VA patients with confirmed COVID-19 treated from Mar 9 until Apr 11.
The patients were assigned to one of three cohorts based on medication exposure: patients treated with hydroxychloroquine alone (97), patients treated with hydroxychloroquine and azithromycin (113), and patients who did not receive hydroxychloroquine (158). The two primary outcomes were death and the need for mechanical ventilation.
Overall, there were 27 deaths (27.8%) in the hydroxychloroquine group, 25 deaths (22.1%) in the hydroxychloroquine/azithromycin group, and 18 deaths (11.4%) in the group that did not receive hydroxychloroquine. Mechanical ventilation occurred in 13.3% of the hydroxychloroquine patients, 6.9% of the hydroxychloroquine/azithromycin patients, and 14.1% of the no-hydroxychloroquine group.
Multilevel statistical analysis of the outcomes showed that, compared with the group that did not receive hydroxychloroquine, the risk of death from any cause was more than two-and-a-half times higher in the hydroxychloroquine patients (adjusted hazard ratio
, 2.61; 95% confidence interval [CI], 1.10 to 6.17; P = 0.03), but was not significantly higher in the hydroxychloroquine/azithromycin patients (adjusted HR, 1.14; 95% CI, 0.56 to 2.32; P = 0.72).
The researchers observed no difference in the risk of ventilation in either the hydroxychloroquine group (adjusted HR, 1.43; 95% CI, 0.53 to 3.79; P = 0.48) or the hydroxychloroquine/ azithromycin patients (adjusted HR, 0.43; 95% CI, 0.16 to 1.12; P = 0.09) compared with the no-hydroxychloroquine group.
"Specifically, hydroxychloroquine use with or without co-administration of azithromycin did not improve mortality or reduce the need for mechanical ventilation in hospitalized patients," the authors wrote. "On the contrary, hydroxychloroquine use alone was associated with an increased risk of mortality compared to standard care alone."
The authors note that hydroxychloroquine, both with and without azithromycin, was more likely to be prescribed to sicker patients, which could play a role in the increased mortality findings. But the increase still persisted in the hydroxychloroquine-only patients when they adjusted the analysis for the propensity of being treated with the drug.
"We are likely seeing that the clinicians treating these patients were choosing hydroxychloroquine-based regimens for patients who were more ill," said Jason Gallagher, PharmD, a clinical professor and infectious diseases specialist at Temple University School of Pharmacy who was not involved in the study. But even with a propensity score adjustment, which attempts to account for differences between groups, "the hydroxychloroquine group had higher odds of death than patients who received standard of care.
"The hydroxychloroquine-azithromycin combination group did not do worse in this analysis, but they didn't do better, either," he added.
Current data don't support early hype
The findings from the study, which is the largest to date to report on outcomes from treating COVID-19 patients with the anti-malaria drug and uses a database that has been used for many different studies, suggest that the hydroxychloroquine/azithromycin combination may not be as promising for treating COVID-19 as some have hoped.
Early excitement about the combination was based on a French study that found hydroxychloroquine was significantly associated with the reduction and disappearance of the COVID-19 viral load in a handful of patients, and that the effect was enhanced by azithromycin. The authors of the study recommended that the repurposed drug, in combination with azithromycin, be used for treating COVID-19 patients, and President Donald Trump soon began touting the combination as a potential "game changer."
The Food and Drug Administration (FDA) issued an Emergency Use Authorization for hydroxychloroquine and chloroquine in late March, allowing for the drugs to be donated to the National Strategic Stockpile for use in COVID-19 patients. The drug is now being used widely to treat COVID-19, both alone and with azithromycin, despite concerns that have been raised about the methodology of the French study, which was not randomized, and results from subsequent studies that have shown little benefit in COVID-19 patients.
There are also concerns about the potential for the hydroxychloroquine/azithromycin combination to prolong the QT interval, which can cause an irregular heartbeat and increase the risk of sudden cardiac arrest. A recent study by researchers with New York University Langone Health found that 11% of COVID-19 patients treated with the hydroxychloroquine/azithromycin combination experienced severely prolonged QT intervals.
Gallagher said the potential for hydroxychloroquine/azithromycin to increase the risk for a potentially fatal heart arrythmia concerns him.
"In the studies of hospitalized patients who receive them, patients receive monitoring," he said. "That is unlikely to occur with outpatient use."
In addition, the interest in hydroxychloroquine, which is also used to treat lupus and rheumatoid arthritis, has led to shortages of the drug, affecting patients who need it for those conditions.
Gallagher said that while he understands people's desperation for a potential treatment for COVID-19, the data right now don't support the use of hydroxychloroquine.
"We need to remember that this is not the first virus that hydroxychloroquine has been tried against. It has in vitro activity against many viruses—Zika, chikungunya, even HIV," he said, referring to lab studies. "But it has never translated into clinical success."
New NIH guidelines agree
New treatment guidelines for COVID-19 released this week by the National Institutes of Health (NIH) have come to the same conclusion.
The guidelines, developed by a panel of experts from federal agencies and professional societies, concluded that the data are insufficient to recommend any antiviral or immunomodulatory therapy for COVID-19 patients who have mild, moderate, or severe illness. The panel recommended that any promising, unapproved, or unlicensed treatment for COVID-19, including drugs like hydroxychloroquine that have been approved for other indications, be studied in well-designed controlled clinical trials.
"Although reports have appeared in the medical literature and the lay press claiming successful treatment of patients with COVID-19 with a variety of agents, definitive clinical trial data are needed to identify optimal treatments for this disease," the panel wrote.
Outside of clinical trials, several of which are now being conducted, the panel recommended against the use of hydroxychloroquine/azithromycin for COVID-19 because of the potential for toxicities.
Share this page: Share Tweet LinkedIn Email Print & PDF
NEWSLETTER SIGN-UP
Get CIDRAP news and other free newsletters.
Sign up now»
OUR UNDERWRITERS
Unrestricted financial support provided by
Bentson Foundation Gilead
Grant support for ASP provided by
bioMérieux
Become an underwriter»
RELATED NEWS ALL NEWS
MAY
20
2020
CDC's COVID-19 reopening guidelines released
MAY
20
2020
As COVID-19 cases near 5 million, WHO sees long road ahead
MAY
20
2020
Critical illness common in New York COVID-19 inpatients: study
MAY
19
2020
Scientists isolate live COVID-19 virus from feces, detect RNA on surfaces
MAIN MENU
HomeNews & PerspectiveInfectious Disease TopicsAntimicrobial StewardshipOngoing Programs
Antimicrobial Stewardship
CEIRS Pandemic Planning
Chronic Wasting Disease
CIDRAP Leadership Forum
COVID-19
Influenza Training
Influenza Vaccines Roadmap
News Publishing
Resilient Drug Supply
Universal Flu Vax Landscape
WHO Roadmap Development
Past Projects
About Us
Staff
Mission
Contact Us
CONNECT WITH US
Newsletter Signup
Facebook
Twitter
Youtube
Email Alerts
CIDRAP - Center for Infectious Disease Research and Policy
Office of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2020 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
CIDRAP | Office of the Vice President for Research | Contact U of M | Privacy Policy -
2020-05-21 at 12:31 AM UTC in What happened to hydroxychloriquine?Home
News & Perspective
Infectious Disease Topics
Antimicrobial Stewardship
Ongoing Programs
About Us
DONATE NOW
FEATURED NEWS TOPICSNovel CoronavirusEbolaMERS-CoVChronic Wasting Disease
Study calls into question use of malaria drug for COVID-19
Filed Under: COVID-19
Chris Dall | News Reporter | CIDRAP News | Apr 23, 2020
Share Tweet LinkedIn Email Print & PDF
hydroxychloroquine_tablets.jpg
Hydroxychloroquine tablets
Bartek Szewczyk / iStock
A retrospective study of patients with COVID-19 at Veterans Affairs (VA) hospitals found no evidence that the antimalaria drug hydroxychloroquine, either with or without the antibiotic azithromycin, reduced mortality or the need for mechanical ventilation.
Researchers also found that hydroxychloroquine alone was associated with increased mortality.
The findings, published this week on the preprint server medRxiv, suggest hydroxychloroquine may not have as much promise for treating COVID-19 patients as initially hoped. The study was not a randomized controlled trial, so the implications of the findings are limited, and the results have not been peer-reviewed. Still, the authors say the results suggest clinicians need to be careful about using the drug in COVID-19 patients.
"Data from ongoing, randomized controlled studies will prove informative when they emerge," they wrote. "Until then, the findings from this retrospective study suggest caution in using hydroxychloroquine in hospitalized COVID-19 patients, particularly when not combined with azithromycin."
No benefit found
For the study, researchers with Columbia VA Health Care System, the University of South Carolina, and the University of Virginia School of Medicine looked at data from 368 VA patients with confirmed COVID-19 treated from Mar 9 until Apr 11.
The patients were assigned to one of three cohorts based on medication exposure: patients treated with hydroxychloroquine alone (97), patients treated with hydroxychloroquine and azithromycin (113), and patients who did not receive hydroxychloroquine (158). The two primary outcomes were death and the need for mechanical ventilation.
Overall, there were 27 deaths (27.8%) in the hydroxychloroquine group, 25 deaths (22.1%) in the hydroxychloroquine/azithromycin group, and 18 deaths (11.4%) in the group that did not receive hydroxychloroquine. Mechanical ventilation occurred in 13.3% of the hydroxychloroquine patients, 6.9% of the hydroxychloroquine/azithromycin patients, and 14.1% of the no-hydroxychloroquine group.
Multilevel statistical analysis of the outcomes showed that, compared with the group that did not receive hydroxychloroquine, the risk of death from any cause was more than two-and-a-half times higher in the hydroxychloroquine patients (adjusted hazard ratio
, 2.61; 95% confidence interval [CI], 1.10 to 6.17; P = 0.03), but was not significantly higher in the hydroxychloroquine/azithromycin patients (adjusted HR, 1.14; 95% CI, 0.56 to 2.32; P = 0.72).
The researchers observed no difference in the risk of ventilation in either the hydroxychloroquine group (adjusted HR, 1.43; 95% CI, 0.53 to 3.79; P = 0.48) or the hydroxychloroquine/ azithromycin patients (adjusted HR, 0.43; 95% CI, 0.16 to 1.12; P = 0.09) compared with the no-hydroxychloroquine group.
"Specifically, hydroxychloroquine use with or without co-administration of azithromycin did not improve mortality or reduce the need for mechanical ventilation in hospitalized patients," the authors wrote. "On the contrary, hydroxychloroquine use alone was associated with an increased risk of mortality compared to standard care alone."
The authors note that hydroxychloroquine, both with and without azithromycin, was more likely to be prescribed to sicker patients, which could play a role in the increased mortality findings. But the increase still persisted in the hydroxychloroquine-only patients when they adjusted the analysis for the propensity of being treated with the drug.
"We are likely seeing that the clinicians treating these patients were choosing hydroxychloroquine-based regimens for patients who were more ill," said Jason Gallagher, PharmD, a clinical professor and infectious diseases specialist at Temple University School of Pharmacy who was not involved in the study. But even with a propensity score adjustment, which attempts to account for differences between groups, "the hydroxychloroquine group had higher odds of death than patients who received standard of care.
"The hydroxychloroquine-azithromycin combination group did not do worse in this analysis, but they didn't do better, either," he added.
Current data don't support early hype
The findings from the study, which is the largest to date to report on outcomes from treating COVID-19 patients with the anti-malaria drug and uses a database that has been used for many different studies, suggest that the hydroxychloroquine/azithromycin combination may not be as promising for treating COVID-19 as some have hoped.
Early excitement about the combination was based on a French study that found hydroxychloroquine was significantly associated with the reduction and disappearance of the COVID-19 viral load in a handful of patients, and that the effect was enhanced by azithromycin. The authors of the study recommended that the repurposed drug, in combination with azithromycin, be used for treating COVID-19 patients, and President Donald Trump soon began touting the combination as a potential "game changer."
The Food and Drug Administration (FDA) issued an Emergency Use Authorization for hydroxychloroquine and chloroquine in late March, allowing for the drugs to be donated to the National Strategic Stockpile for use in COVID-19 patients. The drug is now being used widely to treat COVID-19, both alone and with azithromycin, despite concerns that have been raised about the methodology of the French study, which was not randomized, and results from subsequent studies that have shown little benefit in COVID-19 patients.
There are also concerns about the potential for the hydroxychloroquine/azithromycin combination to prolong the QT interval, which can cause an irregular heartbeat and increase the risk of sudden cardiac arrest. A recent study by researchers with New York University Langone Health found that 11% of COVID-19 patients treated with the hydroxychloroquine/azithromycin combination experienced severely prolonged QT intervals.
Gallagher said the potential for hydroxychloroquine/azithromycin to increase the risk for a potentially fatal heart arrythmia concerns him.
"In the studies of hospitalized patients who receive them, patients receive monitoring," he said. "That is unlikely to occur with outpatient use."
In addition, the interest in hydroxychloroquine, which is also used to treat lupus and rheumatoid arthritis, has led to shortages of the drug, affecting patients who need it for those conditions.
Gallagher said that while he understands people's desperation for a potential treatment for COVID-19, the data right now don't support the use of hydroxychloroquine.
"We need to remember that this is not the first virus that hydroxychloroquine has been tried against. It has in vitro activity against many viruses—Zika, chikungunya, even HIV," he said, referring to lab studies. "But it has never translated into clinical success."
New NIH guidelines agree
New treatment guidelines for COVID-19 released this week by the National Institutes of Health (NIH) have come to the same conclusion.
The guidelines, developed by a panel of experts from federal agencies and professional societies, concluded that the data are insufficient to recommend any antiviral or immunomodulatory therapy for COVID-19 patients who have mild, moderate, or severe illness. The panel recommended that any promising, unapproved, or unlicensed treatment for COVID-19, including drugs like hydroxychloroquine that have been approved for other indications, be studied in well-designed controlled clinical trials.
"Although reports have appeared in the medical literature and the lay press claiming successful treatment of patients with COVID-19 with a variety of agents, definitive clinical trial data are needed to identify optimal treatments for this disease," the panel wrote.
Outside of clinical trials, several of which are now being conducted, the panel recommended against the use of hydroxychloroquine/azithromycin for COVID-19 because of the potential for toxicities.
Share this page: Share Tweet LinkedIn Email Print & PDF
NEWSLETTER SIGN-UP
Get CIDRAP news and other free newsletters.
Sign up now»
OUR UNDERWRITERS
Unrestricted financial support provided by
Bentson Foundation Gilead
Grant support for ASP provided by
bioMérieux
Become an underwriter»
RELATED NEWS ALL NEWS
MAY
20
2020
CDC's COVID-19 reopening guidelines released
MAY
20
2020
As COVID-19 cases near 5 million, WHO sees long road ahead
MAY
20
2020
Critical illness common in New York COVID-19 inpatients: study
MAY
19
2020
Scientists isolate live COVID-19 virus from feces, detect RNA on surfaces
MAIN MENU
HomeNews & PerspectiveInfectious Disease TopicsAntimicrobial StewardshipOngoing Programs
Antimicrobial Stewardship
CEIRS Pandemic Planning
Chronic Wasting Disease
CIDRAP Leadership Forum
COVID-19
Influenza Training
Influenza Vaccines Roadmap
News Publishing
Resilient Drug Supply
Universal Flu Vax Landscape
WHO Roadmap Development
Past Projects
About Us
Staff
Mission
Contact Us
CONNECT WITH US
Newsletter Signup
Facebook
Twitter
Youtube
Email Alerts
CIDRAP - Center for Infectious Disease Research and Policy
Office of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2020 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
CIDRAP | Office of the Vice President for Research | Contact U of M | Privacy Policy
